These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 14730339)
1. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Powell JL; Bunin NJ; Callahan C; Aplenc R; Griffin G; Grupp SA Bone Marrow Transplant; 2004 Mar; 33(6):651-7. PubMed ID: 14730339 [TBL] [Abstract][Full Text] [Related]
2. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001 [TBL] [Abstract][Full Text] [Related]
3. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. van Esser JW; Niesters HG; van der Holt B; Meijer E; Osterhaus AD; Gratama JW; Verdonck LF; Löwenberg B; Cornelissen JJ Blood; 2002 Jun; 99(12):4364-9. PubMed ID: 12036863 [TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. van Esser JW; van der Holt B; Meijer E; Niesters HG; Trenschel R; Thijsen SF; van Loon AM; Frassoni F; Bacigalupo A; Schaefer UW; Osterhaus AD; Gratama JW; Löwenberg B; Verdonck LF; Cornelissen JJ Blood; 2001 Aug; 98(4):972-8. PubMed ID: 11493441 [TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Meijer E; Cornelissen JJ Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928 [TBL] [Abstract][Full Text] [Related]
7. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Meij P; van Esser JW; Niesters HG; van Baarle D; Miedema F; Blake N; Rickinson AB; Leiner I; Pamer E; Lowenberg B; Cornelissen JJ; Gratama JW Blood; 2003 Jun; 101(11):4290-7. PubMed ID: 12576337 [TBL] [Abstract][Full Text] [Related]
8. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716 [TBL] [Abstract][Full Text] [Related]
9. Clinical epidemiology of Epstein-Barr virus-associated Lymphoproliferative Disorders (EBV-LPDs) in hospitalized children: A six-year multi-institutional study in China. Dilmurat D; Wang X; Gao L; Tian J; Ai J; Zhang L; Liu M; Feng G; Zeng Y; Wang R; Xie Z Ital J Pediatr; 2024 Jul; 50(1):125. PubMed ID: 38956696 [TBL] [Abstract][Full Text] [Related]
10. [Clinical and pathological features of 13 children with Epstein-Barr virus-positive lymphoproliferative disease]. Chen TM; Deng ZJ; Hu B; Hu HL; Chen HY; Li SY; Liu G Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):759-764. PubMed ID: 30293280 [No Abstract] [Full Text] [Related]
11. Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma. Awaya N; Adachi A; Mori T; Kamata H; Nakahara J; Yokoyama K; Yamada T; Kizaki M; Sakamoto M; Ikeda Y; Okamoto S Leuk Res; 2006 Aug; 30(8):1059-62. PubMed ID: 16330097 [TBL] [Abstract][Full Text] [Related]
12. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. van Esser JW; Niesters HG; Thijsen SF; Meijer E; Osterhaus AD; Wolthers KC; Boucher CA; Gratama JW; Budel LM; van der Holt B; van Loon AM; Löwenberg B; Verdonck LF; Cornelissen JJ Br J Haematol; 2001 Jun; 113(3):814-21. PubMed ID: 11380475 [TBL] [Abstract][Full Text] [Related]
13. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Pakakasama S; Eames GM; Morriss MC; Huls MH; Rooney CM; Heslop HE; Krance RA Transplantation; 2004 Sep; 78(5):755-7. PubMed ID: 15371682 [TBL] [Abstract][Full Text] [Related]
14. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies. Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569 [TBL] [Abstract][Full Text] [Related]
16. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142 [TBL] [Abstract][Full Text] [Related]
17. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Cohen J; Gandhi M; Naik P; Cubitt D; Rao K; Thaker U; Davies EG; Gaspar HB; Amrolia PJ; Veys P Br J Haematol; 2005 Apr; 129(2):229-39. PubMed ID: 15813851 [TBL] [Abstract][Full Text] [Related]